(518.3 SFU) against RPE65 at baseline only, while all subsequent timepoints were negative. The positive T cell responses observed at baseline prior to vector administration are unlikely to be related to gene transfer. Considering the cumulative immune response data collected from the two validated immunoassays performed here, the Phase 3 trial provided results supporting the immunologic tolerability of the delivery of AAV2 vector to the subretinal space in the eye to treat inherited retinal dystrophy due to mutations in RPE65. Efforts are ongoing to correlate these findings with available efficacy data.
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Translating an Optogenetic Gene Therapy Approach for Treatment of Neuropathic Pain in Humans
Chris Towne, Jesus Aguado, Annie Arguello, Claire Discenza, Tim Galfin, Stephan Gehrke, Sabeena Khan, Michael Kaplitt Circuit Therapeutics Inc, Menlo Park, CA Optogenetics has been established as a powerful tool to study the central and peripheral nervous systems with its potential for directly treating human disease tantalizingly on the horizon. Optogenetic inhibition of pain in mice has been shown to be effective and provides an attractive initial application. We aim to translate this approach to treat neuropathic pain in humans. Firstly, we demonstrated that the inhibitory opsin, NpHR, delivered by intraneural injections of AAV6 could reduce pain (mechanical allodynia) in a clinically meaningful paradigm i.e. vector delivery after establishment of neuropathic pain in the chronic constriction injury (CCI) model. The inhibitory opsin, iC1C2 (a chloride channel requiring less light than NpHR to pass currents) could also reduce pain in this system. We next tested a surgical approach more amenable to patients than nerve injection. Lumbar puncture is a routine clinical practice and AAV8 delivery by this method results in efficient gene delivery to sensory neurons in rodents, dogs and pigs. We found that intrathecal administration of AAV8 expressing iC1C2 could decrease mechanical allodynia in the CCI mouse model. The magnitude of pain inhibition correlated with transduction levels and only 10% transduction of sensory neurons was required for pain relief. To further validate this approach we utilized a second rodent pain model with translational relevance. The mouse tibia fracture/cast immobilization model of Complex Regional Pain Syndrome (CRPS) presents extreme allodynia and recapitulates human disease effectively. We found that intrathecal delivery of AAV8 encoding iC1C2 following development of the CRPS model resulted in light-mediated pain inhibition. Taken together, our results confirm optogenetic therapy for neuropathic pain as an attractive clinical application of this technology.
TFEB-Mediated Clearance of the Lipofuscin Fluorophore A2E
Ivana Trapani, Elisabetta Toriello, Renato Minopoli, Alberto Auricchio
Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy
Abnormal accumulation of various by-products of the visual cycle, including the diretinoid-pyridinium-ethanolamine (A2E), in retinal pigment epithelium (RPE) is an hallmark of both Stargardt disease (STGD) and age-related macular degeneration (AMD). This is responsible for RPE and, consequently, photoreceptor (PR) cell death. A2E storage in RPE lysosomes has been shown to reduce both the capacity of RPE to degrade phagocytized PR outer segments and autophagosome biogenesis, trafficking and autophagic flux. The transcription factor EB (TFEB) is a master regulator of cellular clearance. Here we tested if TFEB overexpression induces A2E clearance from the RPE cells. We have generated a plasmid encoding for a double-serine mutant (S142A, S211A) form of TFEB, which is constitutively active. We have transfected this plasmid in the human RPE-derived ARPE19 cells to evaluate TFEB activation of its transcriptional targets and ability to clear A2E after loading. We found that TFEB overexpression in ARPE19 cells results in the induction of TFEB transcriptional targets involved in cellular clearance. Importantly, TFEB overexpression in ARPE19 cells was associated with reduction of intracellular A2E accumulation. Taken together these results suggest that TFEB overexpression is an effective strategy to promote A2E clearance in vitro. Further studies will clarify if this holds true in vivo. These results may have implications for the therapy of both STGD and the more common AMD.
AAV Mediated Gene Therapy to Modulate Neurotropic Factors in the Retina and in Neuronal Cells in Culture
Neurotrophic factors, particularly Brain Derived Neurotrophic Factor (BDNF) and its high affinity receptor TrkB, play an important role in protecting the retinal ganglion cells (RGCs) in glaucoma. Translation of the immense neuro-protective potential of BDNF/ TrkB activation has been largely unsuccessful and gene therapy to modulate BDNF and TrkB have also shown only short-lived protective effects on the RGCs. PTPN11 phosphatase plays a key role in the regulation of BDNF/TrkB signaling in the retina. Here, we investigated the effects of PTPN11 modulation involving both over-expression and knock-down paradigms on the TrkB activation. PTPN11 and PTPN11-shRNA sequences were separately incorporated into the AAV2 vector under cytomegalovirus chicken β actin hybrid promoter linked with green fluorescent protein (GFP). SH-SY5Y cells were transfected with each of the PTPN11 modulating and control GFP constructs. PTPN11 over-expression resulted in significant reduced TrkB phosphorylation and accordingly reduced viability of the SH-SY5Y cells was observed while PTPN11 knockdown did not exhibit any significant effects on either TrkB phosphorylation or cellular survival. PTPN11 over-expression in neuronal cells was also accompanied by elevation of GADD, PERK and XBP-1 endoplasmic reticulum (ER) stress marker proteins as detected using western blotting. The roles of PTPN11 and TrkB in mediating ER stress were evaluated by treating cells with PTPN11 inhibitor (PHPS1) or TrkB agonist (7,8-dihydroxyflavone) independently, both of which ablated the up-regulation of ER stress proteins upon PTPN11 overexpression. The effects of PTPN11 over-expression on the rat retina were evaluated by administering PTPN11 AAV2 construct along with corresponding GFP controls individually into the rat eyes. Briefly, 5µl of AAV2 constructs were injected intravitreally into SD rats (2x10 10 vg). Anti-GFP staining in retinal sections demonstrated AAV2 transduction in the RGC layer. Anti-NeuN/ anti-PTPN11 staining confirmed the ganglion cell specific over-expression of PTPN11. Rat retinas were assessed for inner retinal functional changes using scotopic threshold response (STR) measurements. Retinal structural changes were assessed using histological analysis. Results indicate that pSTR amplitude which primarily reflects the function of the RGCs was significantly diminished in the PTPN11 over-expression model. Hematoxylin and eosin staining also revealed degenerative changes primarily associated with the inner retina. Assessment of optic nerve sections using Bielschowsky's staining further identified reduced axonal density. Concluding, our findings strongly indicate that PTPN11 genetic modulation holds the promise to regulate neuronal cell survival through its effects on TrkB activation. PTPN11 over-expression exerts detrimental impact on the inner retinal health which has significant implications in glaucoma and other retinal disorders. Further studies involving rescue of the disease phenotype
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Therapeutic Age-related macular degeneration, otherwise known as AMD, is a progressive, irreversible eye condition in which the retina is permanently damaged by either atrophy of its pigment epithelial layer (dry AMD) or abnormal blood vessel growth in the retina's membrane (wet AMD). Wet AMD, the more advanced, severe version of the disease, is induced by overexposure to vascular endothelial growth factor (VEGF) in the eye. This VEGF-induced blood vessel growth leads to rupture and leaking of the retina's membrane, endangering the integrity of the macula, which is vital for acute central vision. Once the macula is scarred and central vision is lost, it cannot be recovered. Current treatments for wet AMD include several drugs (i.e. lucentis) that inhibit VEGF, yielding a reduction in retinal thickness and moderate increases in visual acuity. While these treatments succeed in prohibiting disease progression, they require frequent intravitreal injections. In the future, the goal is to prevent disease progression while avoiding repeated injections with the use of therapeutic gene transfer.
To develop this new generation of AMD therapeutic, we sought to create an efficacious AAV vector expressing anti-VEGF antibody via systematic optimization of all vector elements. Six promoters, 12 coding sequence variants, an F2A linker, and 3 internal ribosome entry sites (IRES) were evaluated for tissue-specific expression in mouse eye. Mean expression from the 2 best promoters, UbC and CB7, was 400 and 450 ng/mg of eye lysate, respectively, compared with the CMV promoter at 10 ng/mg. In the context of a CMV promoter, mean expression for best-performing IRES (EMCV) was 2 ng/mg of tissue lysate, which was 5-fold lower than that from the construct containing an F2A linker (10 ng/mg). The best-expressing coding sequence variants, named AMD11 and AMD42, yielded 12 and 13 ng/mg of tissue lysate, respectively.
In order to identify a clinical candidate vector, the best-performing elements were combined to generate 4 additional vectors, which were evaluated in both eyes of 8 rhesus macaques for each vector. Following subretinal injection with 1x10 11 GC/eye, anterior chamber fluid was sampled on days 15 and 29. Among the 16 injected eyes, average expression of AAV-UbC-AMD11 was 473.6 ng/ml (ranging from 123.5 to 933 ng/ml) of anterior chamber fluid on day 15 after vector administration and 546.2 ng/ml (262 to 1263 ng/ml) on day 29. Average expression of AAV-UbC-AMD42 was 360.6 ng/ml (144.6 to 646.8 ng/ml) and 536.8 ng/ml (238.3 to 920.7 ng/ml) on days 15 and 29, respectively. For AAV-CB7-AMD11, average expression on days 15 and 29 was 972.4 ng/ml (495.9 to 1684.7 ng/ml) and 1100.3 ng/ml (422.3 to 2187.8 ng/ml). The final vector, AAV-CB7-AMD42, expressed at 1922.2 ng/ml (707.9 to 2892.7 ng/ml) on day 15 and 1396 ng/ml (431.2 to 2346.4 ng/ml) on day 29. After final selection, the clinical candidate vector will be evaluated in formal nonclinical studies prior to a clinical trial. Selection criteria will include expression levels and vector yields. Chimeric antigen receptor (CAR) T cell therapy has recently emerged as an attractive approach for the treatment of CD19-expressing hematological malignancies. However extending the success of this strategy to other targets has proven to be more complicated that simply replacing the scFv. To address this issue we have implemented a form of adaptive CAR design whereby a series of sequential modifications are made to a single domain and subsequently tested in vitro and in vivo to assess activity. We illustrate the utility of such a strategy using our published CAR-PSCA (Anurathapan U. et al, Mol Ther. 2014) as a template (CAR-PSCA v1.0) with subsequent iterations coded as versions 2.0, 3.0, 4.0 and 5.0. We now demonstrate how modifications made to a single CAR structural domain can result in enhanced (i) T cell migration, (ii) antigen recognition, and (iii) cell phenotype, ultimately producing superior anti-tumor effects. First, with CAR v2.0 and v3.0 we were able to improve T cell migration, which was evident in NSG mice engrafted s.c. with Capan-1 and treated i.v. with FFluc+ T cells. Ten days post CAR administration we saw a 2 log increase in the T cell signal at the tumor site (4.5±2. 
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Adaptive CAR T Cell Design
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Development Inadequate antigen delivery is one of the major limitations of modern cancer vaccine vectors. To overcome this challenge, we exploited Salmonella Pathogenicity Island 2 (SPI2) and its type III secretion system (T3SS) to deliver a tumor-associated antigen (TAA) of choice into the cytosol of antigen-presenting cells (APC) in situ. The goal of this study was to explore and exploit the potential of
